Skip to search formSkip to main contentSkip to account menu

BL-1020

Known as: BL 1020, BL1020 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
In schizophrenia, a psychiatric disorder that affects approximately 1% of the global population and is associated with… 
2010
2010
An Open-Label Tolerability Study of BL-1020 Antipsychotic: A Novel Gamma Aminobutyric Acid Ester of Perphenazine
Background:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong… 
2010
2010
RESULTS OF PHASE 2B EAGLE TRIAL; A DOUBLE BLIND PLACEBO CONTROL STUDY EVALUATING THE EFFICACY AND SAFETY OF BL-1020, A GABA ENHANCED ANTIPSYCHOTIC FOR THE TREATMENT OF SCHIZOPHRENIA
2009
2009
BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia
2009
2009
BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D 2 receptor occupancy
BL-1020 is a potentially novel antipsychotic, which comprises the typical antipsychotic perphenazine linked by an ester bound to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)